Results of treatment of laryngeal cancer.
Eighty-one laryngeal cancer patients treated at our clinic during the past ten years were studied clinically. The proportion of patients in their sixties was highest and the number of males was much larger than that of females, at a ratio of 15:1. Laryngeal cancer was classified as glottic, supraglottic, and subglottic in 58, 19, and 4 cases, respectively, and glottic cancer patients accounted for more than half of these. The cumulative 5-year survival rate in all patients was 79.6%, and the rates in glottic and supraglottic cancer patients were 82.2% and 83.3%, respectively. Cumulative 5-year survival rates in patients in Stages I, II, III and IV were 83.7%, 83.9%, 83.3%, and 55.5%, respectively. Recurrence after radiotherapy was controlled by salvage operations satisfactorily in Stages I and II, but the prognosis of recurrent cancer was poor for patients in Stages III and IV. A selective review is given.
Suzuki
H
H
Department of Otolaryngology, Yamagata Prefectural Central Hospital, Japan.
Hasegawa
T
T
Sano
R
R
Kim
Y
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary / Q000601:surgery*; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005931:Glottis / Q000473:pathology; D006801:Humans; D007822:Laryngeal Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D007825:Laryngectomy; D053685:Laser Therapy; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome; D014801:Vitamin A / Q000627:therapeutic use
D003037:Cobalt Radioisotopes; D014801:Vitamin A; D005472:Fluorouracil